Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mitotech S A holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This matter is being reviewed by 1 distinct examiner, showing a highly specific point of contact within the patent office for the company's current mitochondrial research applications.
The prosecution is occurring within a distinct art unit. JOHNSON, CHRISTOPHER LINDSAY is the busiest examiner for the company, with the 1 pending office action currently assigned. This single action represents the entirety of the active examination matters for the portfolio.
This indicates that the company's current intellectual property activity is centered on a specific biotechnological development. A practitioner should leverage the examiner's specialized knowledge to advance the application, ensuring that all technical arguments are precisely aligned with the examiner's expectations for pharmaceutical patentability.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 46.9% | +81.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17916702 | Use of Mitochondria-Targeted Antioxidants to Treat Severe Inflammatory Conditions | JOHNSON, CHRISTOPHER LINDSAY | 45d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17916702 | Use of Mitochondria-Targeted Antioxidants to Treat Severe Inflammatory Conditions | JOHNSON, CHRISTOPHER LINDSAY | 45d overdue |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17916702 | Use of Mitochondria-Targeted Antioxidants to Treat Severe Inflammatory Conditions | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §102§112 | Final Rejection | 45d overdue | Pending | Oct 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial